Literature DB >> 10873075

Imaging of soft-tissue tumors using L-3-[iodine-123]iodo-alpha-methyl-tyrosine single photon emission computed tomography: comparison with proliferative and mitotic activity, cellularity, and vascularity.

P L Jager1, B E Plaat, E G de Vries, W M Molenaar, W Vaalburg, D A Piers, H J Hoekstra.   

Abstract

The radiolabeled amino acid L-3-[123I]-iodo-alpha-methyltyrosine (IMT) is a new tumor tracer that accumulates in many tumors and is suitable for single photon emission computed tomography (SPECT) imaging. Using IMT SPECT, we studied 32 patients with a soft-tissue tumor suspected to be a soft-tissue sarcoma to determine whether: (a) tumors can be visualized; (b) benign and malignant lesions can be distinguished; and (c) IMT uptake is related to tumor grade and proliferation. Whole-body imaging was performed 15 min after administration of 300 MBq IMT, biopsy, or resection 1-2 weeks later. IMT uptake was quantified using a region-of-interest method resulting in tumor:background (T:B) ratios. These were compared with tumor grade, mitotic index, tumor cellularity, vascularity, and the Ki-67 proliferation index. Eleven patients had a benign tumor, and 21 patients had a soft-tissue sarcoma. Six benign tumors demonstrated minor IMT uptake, and five lipomas had no uptake. All malignant tumors had high uptake and were clearly visualized. T:B ratios in malignant tumors (3.83 +/- 1.16) were higher (P < 0.001) than in benign tumors (1.52 +/- 0.60). Small (<5 mm) metastases in two patients were not detected. Taking the T:B ratio 2.0 as the cutoff level, the sensitivity for detection of malignancy was 100%, and specificity was 88%. IMT uptake correlated with histological grade (r = 0.82; P < 0.001), mitotic index (r = 0.75; P < 0.001), tumor cellularity (r = 0.73; P < 0.01), and with the Ki-67 proliferation index (r = 0.63; P < 0.01). In conclusion, IMT SPECT visualized all soft-tissue sarcomas. Uptake in sarcomas was clearly higher than in benign lesions, yielding 100% sensitivity for detection of malignancy at 88% specificity. Uptake increased with higher tumor grade and higher proliferation rate.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873075

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  6 in total

1.  Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours.

Authors:  Michail Plotkin; Holger Amthauer; Julia Eisenacher; Reinhard Wurm; Roger Michel; Peter Wust; Florian Stockhammer; Rainer Röttgen; Matthias Gutberlet; Juri Ruf; Roland Felix
Journal:  Neuroradiology       Date:  2005-01-04       Impact factor: 2.804

2.  (99m)Tc-EC-guanine: synthesis, biodistribution, and tumor imaging in animals.

Authors:  David J Yang; Kaoru Ozaki; Chang-Sok Oh; Ali Azhdarinia; Thomas Yang; Megumi Ito; Allison Greenwell; Jerry Bryant; Saady Kohanim; Vincenzo K Wong; E Edmund Kim
Journal:  Pharm Res       Date:  2005-08-24       Impact factor: 4.200

3.  Combined SPECT/CT imaging using 123I-IMT in the detection of recurrent or persistent head and neck cancer.

Authors:  Michail Plotkin; Reinhard Wurm; Julia Eisenacher; Katarzyna Szerewicz; Roger Michel; Lorenz Schlenger; Maciej Pech; Timm Denecke; David Kuczer; Annet Bischoff; Roland Felix; Holger Amthauer
Journal:  Eur Radiol       Date:  2005-06-28       Impact factor: 5.315

4.  ⁹⁹mTc-N4amG: synthesis biodistribution and imaging in breast tumor-bearing rodents.

Authors:  Ning Tsao; Mithu Chanda; Dong-Fang Yu; Hiroaki Kurihara; Yin-Han Zhang; Richard Mendez; David J Yang
Journal:  Appl Radiat Isot       Date:  2012-10-11       Impact factor: 1.513

Review 5.  Amino Acid Metabolism as a Target for Breast Cancer Imaging.

Authors:  Gary A Ulaner; David M Schuster
Journal:  PET Clin       Date:  2018-07

6.  Target localization using scanner-acquired SPECT data.

Authors:  Justin R Roper; James E Bowsher; Joshua M Wilson; Timothy G Turkington; Fang-Fang Yin
Journal:  J Appl Clin Med Phys       Date:  2012-05-10       Impact factor: 2.102

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.